Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Butterfield, Lisa H ^a   Economou, James S ^b   Gamblin, T C ^c   Geller, David A ^d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha fetoprotein; Cancer vaccine; Hepatocellular cancer; Prime boost

Indexed keywords

ALPHA FETOPROTEIN; CANCER VACCINE; CHEMOKINE; CYTOKINE; GROWTH FACTOR; HLA A2 ANTIGEN; NEUTRALIZING ANTIBODY; PLASMID DNA; PRIMER DNA; VIRUS VECTOR; DNA VACCINE; GROWTH PROMOTOR;

ADENOVIRUS; AGED; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RECURRENCE; CANCER SCREENING; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; LAPAROSCOPIC SURGERY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER LOBECTOMY; MALE; MEDICAL HISTORY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; REGULATORY T LYMPHOCYTE; VACCINE PRODUCTION; VERY ELDERLY; ADENOVIRIDAE; ANTIBODY PRODUCTION; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; LIVER TUMOR;

ADENOVIRIDAE; ALPHA-FETOPROTEINS; ANTIBODY FORMATION; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CHEMOKINES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GROWTH SUBSTANCES; HUMANS; LIVER NEOPLASMS; VACCINES, DNA;

EID: 84899635997     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-86     Document Type: Article

References (26)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491. 10.1200/JCO.2008.20.7753, 2668555, 19224838.
3. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS. Liver Cancer Network: Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003, 98:2060-2063.
4. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010, 42(Suppl 3):S206-214. 3392755, 20547305.
5. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763. 10.1053/j.gastro.2008.02.090, 18471552.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. SHARP Investigative Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514.
7. Siegel AB, Olsen SK, Magun A, Brown RS. Sorafenib: where do we go from here?. Hepatology 2010, 52:360-369. 10.1002/hep.23633, 3605708, 20578152.
8. Song R, Ikeguchi M, Zhou G, Kuo MT. Identification and characterization of a hepatoma cell-specific enhancer in the mouse multidrug resistance mdr1b promoter. J Biol Chem 1995, 270:25468-25474. 10.1074/jbc.270.43.25468, 7592715.
9. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998, 27:407-414. 10.1002/hep.510270214, 9462638.
10. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med 2001, 226:377-408.
11. Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther 2002, 2:709-735. 10.1586/14737140.2.6.709, 12503217.
12. Um SH, Mulhall C, Alisa A, Ives AR, Karani J, Williams R, Bertoletti A, Behboudi S. Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol 2004, 173:1772-1778. 10.4049/jimmunol.173.3.1772, 15265907.
13. Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS. Alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001, 61:8782-8786.
14. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, Economou JS. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clinical Cancer Res 2003, 9:5902-5908.
15. Butterfield LH, Ribas A, Potter DM, Economou JS. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol Immunother 2007, 56:1931-1943. 10.1007/s00262-007-0337-9, 17522860.
16. Evdokimova VN, Liu Y, Potter DM, Butterfield LH. AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. J Immunother 2007, 30:425-437. 10.1097/CJI.0b013e31802fd8e2, 3612834, 17457217.
17. Vollmer CM, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999, 59:3064-3067.
18. Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M, Makowiec F, Obermaier R, Hopt UT, Blum HE, Spangenberg HC. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology 2008, 48:1821-1833. 10.1002/hep.22535, 19003875.
19. Greten TF, Ormandy LA, Fikuart A, Hochst B, Henschen S, Horning M, Manns MP, Korangy F. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010, 33:211-218. 10.1097/CJI.0b013e3181bb499f, 20139774.
20. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166. 10.1016/j.ccr.2008.01.013, 18242515.
21. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006, 12:2817-2825. 10.1158/1078-0432.CCR-05-2856, 16675576.
22. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010, 70:8368-8377. 10.1158/0008-5472.CAN-10-1322, 2970736, 20940398.
23. Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008, 180:3122-3131. 10.4049/jimmunol.180.5.3122, 18292535.
24. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105. 10.1200/JCO.2009.25.0597, 2834462, 20100959.
25. Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 1999, 59:3134-3142.
26. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004, 11:351-357. 371218, 15013987.